Lowering LDL-C important for younger patients

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • The risk for cardiovascular events linked to apolipoprotein B (apoB) particles decreases with age, underscoring the importance of therapy to lower low-density lipoprotein (LDL) levels for younger patients with elevated lipids.

Why this matters

  • High concentrations of the apoB lipoproteins increase the risk for cardiovascular disease.

Study design

  • Researchers determined the associations for total cholesterol, LDL‐cholesterol (LDL-C), non‐high‐density lipoprotein‐cholesterol (non‐HDL‐C), apoB, apolipoprotein A‐I (apoA‐I), and HDL‐C with myocardial infarction (MI) at different ages (11,760 control patients, 8998 patients with myocardial infarction [MI]).

  • They then used logistic regression to compute the MI OR for 1 SD change in each lipid marker by decade from <40 to >70 y of age.

  • Funding: The Doggone Foundation.

Key results

  • The cardiovascular risk associated with the atherogenic lipid markers differed at different ages.

  • There was a significant decline in the OR for total cholesterol, LDL‐C, non‐HDL‐C, and apoB with increases in age (P<.001); ORs associated with apoA‐I and HDL‐C were consistent across the age groups.

Limitations

  • This was not a prospective observational study.